Smart biomaterials design for tissue engineering and regenerative medicine

Mark E. Furth, Anthony Atala, Mark E. Van Dyke

Research output: Contribution to journalArticle

251 Citations (Scopus)

Abstract

As a prominent tool in regenerative medicine, tissue engineering (TE) has been an active field of scientific research for nearly three decades. Clinical application of TE technologies has been relatively restricted, however, owing in part to the limited number of biomaterials that are approved for human use. While many excellent biomaterials have been developed in recent years, their translation into clinical practice has been slow. As a consequence, many investigators still employ biodegradable polymers that were first approved for use in humans over 30 years ago. During normal development tissue morphogenesis is heavily influenced by the interaction of cells with the extracellular matrix (ECM). Yet simple polymers, while providing architectural support for neo-tissue development, do not adequately mimic the complex interactions between adult stem and progenitor cells and the ECM that promote functional tissue regeneration. Future advances in TE and regenerative medicine will depend on the development of "smart" biomaterials that actively participate in the formation of functional tissue. Clinical translation of these new classes of biomaterials will be supported by many of the same evaluation tools as those developed and described by Professor David F. Williams and colleagues over the past 30 years.

Original languageEnglish
Pages (from-to)5068-5073
Number of pages6
JournalBiomaterials
Volume28
Issue number34
DOIs
StatePublished - Dec 1 2007
Externally publishedYes

Fingerprint

Regenerative Medicine
Biocompatible Materials
Tissue Engineering
Tissue engineering
Biomaterials
Tissue
Extracellular Matrix
Polymers
Tissue regeneration
Biodegradable polymers
Adult Stem Cells
Engineering technology
Morphogenesis
Cell Communication
Regeneration
Stem Cells
Research Personnel
Technology
Research

Keywords

  • Clinical
  • Extracellular matrix
  • Human use
  • Intelligent biomaterials
  • Smart

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering

Cite this

Smart biomaterials design for tissue engineering and regenerative medicine. / Furth, Mark E.; Atala, Anthony; Van Dyke, Mark E.

In: Biomaterials, Vol. 28, No. 34, 01.12.2007, p. 5068-5073.

Research output: Contribution to journalArticle

Furth, Mark E. ; Atala, Anthony ; Van Dyke, Mark E. / Smart biomaterials design for tissue engineering and regenerative medicine. In: Biomaterials. 2007 ; Vol. 28, No. 34. pp. 5068-5073.
@article{d940f9ca1a474616baae08c1187e1500,
title = "Smart biomaterials design for tissue engineering and regenerative medicine",
abstract = "As a prominent tool in regenerative medicine, tissue engineering (TE) has been an active field of scientific research for nearly three decades. Clinical application of TE technologies has been relatively restricted, however, owing in part to the limited number of biomaterials that are approved for human use. While many excellent biomaterials have been developed in recent years, their translation into clinical practice has been slow. As a consequence, many investigators still employ biodegradable polymers that were first approved for use in humans over 30 years ago. During normal development tissue morphogenesis is heavily influenced by the interaction of cells with the extracellular matrix (ECM). Yet simple polymers, while providing architectural support for neo-tissue development, do not adequately mimic the complex interactions between adult stem and progenitor cells and the ECM that promote functional tissue regeneration. Future advances in TE and regenerative medicine will depend on the development of {"}smart{"} biomaterials that actively participate in the formation of functional tissue. Clinical translation of these new classes of biomaterials will be supported by many of the same evaluation tools as those developed and described by Professor David F. Williams and colleagues over the past 30 years.",
keywords = "Clinical, Extracellular matrix, Human use, Intelligent biomaterials, Smart",
author = "Furth, {Mark E.} and Anthony Atala and {Van Dyke}, {Mark E.}",
year = "2007",
month = "12",
day = "1",
doi = "10.1016/j.biomaterials.2007.07.042",
language = "English",
volume = "28",
pages = "5068--5073",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "34",

}

TY - JOUR

T1 - Smart biomaterials design for tissue engineering and regenerative medicine

AU - Furth, Mark E.

AU - Atala, Anthony

AU - Van Dyke, Mark E.

PY - 2007/12/1

Y1 - 2007/12/1

N2 - As a prominent tool in regenerative medicine, tissue engineering (TE) has been an active field of scientific research for nearly three decades. Clinical application of TE technologies has been relatively restricted, however, owing in part to the limited number of biomaterials that are approved for human use. While many excellent biomaterials have been developed in recent years, their translation into clinical practice has been slow. As a consequence, many investigators still employ biodegradable polymers that were first approved for use in humans over 30 years ago. During normal development tissue morphogenesis is heavily influenced by the interaction of cells with the extracellular matrix (ECM). Yet simple polymers, while providing architectural support for neo-tissue development, do not adequately mimic the complex interactions between adult stem and progenitor cells and the ECM that promote functional tissue regeneration. Future advances in TE and regenerative medicine will depend on the development of "smart" biomaterials that actively participate in the formation of functional tissue. Clinical translation of these new classes of biomaterials will be supported by many of the same evaluation tools as those developed and described by Professor David F. Williams and colleagues over the past 30 years.

AB - As a prominent tool in regenerative medicine, tissue engineering (TE) has been an active field of scientific research for nearly three decades. Clinical application of TE technologies has been relatively restricted, however, owing in part to the limited number of biomaterials that are approved for human use. While many excellent biomaterials have been developed in recent years, their translation into clinical practice has been slow. As a consequence, many investigators still employ biodegradable polymers that were first approved for use in humans over 30 years ago. During normal development tissue morphogenesis is heavily influenced by the interaction of cells with the extracellular matrix (ECM). Yet simple polymers, while providing architectural support for neo-tissue development, do not adequately mimic the complex interactions between adult stem and progenitor cells and the ECM that promote functional tissue regeneration. Future advances in TE and regenerative medicine will depend on the development of "smart" biomaterials that actively participate in the formation of functional tissue. Clinical translation of these new classes of biomaterials will be supported by many of the same evaluation tools as those developed and described by Professor David F. Williams and colleagues over the past 30 years.

KW - Clinical

KW - Extracellular matrix

KW - Human use

KW - Intelligent biomaterials

KW - Smart

UR - http://www.scopus.com/inward/record.url?scp=34748838460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34748838460&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2007.07.042

DO - 10.1016/j.biomaterials.2007.07.042

M3 - Article

C2 - 17706763

AN - SCOPUS:34748838460

VL - 28

SP - 5068

EP - 5073

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 34

ER -